Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Botulinum Toxin vs Fasciotomy for CECS
NCT03339921Phase 3Terminated
- Sponsor
- 375th Medical Group
- Start
- Dec 2018
- Primary completion
- May 2020
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label trial of botulinum toxin type A in Chronic Exertional Compartment Syndrome (CECS) (2 arms), sponsored by 375th Medical Group. Primary endpoint: Lower Extremity Functional Index at 6 months. Started Dec 2018; status: terminated.
02
Drugs
botulinum toxin type A
03
Conditions
Chronic Exertional Compartment Syndrome (CECS)
Beyond the preview
Go deeper on NCT03339921.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03339921.